Buying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are hard to find, but they can generate massive returns over long periods. Just think about the savvy investors who held MustGrow Biologics Corp. (CVE:MGRO) shares for the last five years, while they gained 414%. If that doesn't get you thinking about long term investing, we don't know what will. It's also good to see the share price up 104% over the last quarter.

Since it's been a strong week for MustGrow Biologics shareholders, let's have a look at trend of the longer term fundamentals.

Check out our latest analysis for MustGrow Biologics

MustGrow Biologics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In the last 5 years MustGrow Biologics saw its revenue grow at 98% per year. Even measured against other revenue-focussed companies, that's a good result. Arguably, this is well and truly reflected in the strong share price gain of 39%(per year) over the same period. It's never too late to start following a top notch stock like MustGrow Biologics, since some long term winners go on winning for decades. So we'd recommend you take a closer look at this one, but keep in mind the market seems optimistic.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

We're pleased to report that MustGrow Biologics shareholders have received a total shareholder return of 48% over one year. That's better than the annualised return of 39% over half a decade, implying that the company is doing better recently. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - MustGrow Biologics has 4 warning signs (and 1 which makes us a bit uncomfortable) we think you should know about.